Australia's most trusted
source of pharma news
Thursday, 21 November 2024
Posted 21 November 2024 AM
Staring down a patent cliff, MSD says it's ready to share results of its subcutaneous version of Keytruda with "regulatory authorities worldwide" as it looks to maximise the mega blockbuster's growth potential.
It marks close to eight years since the PD-1 inhibitor - which has since become the top-earning PBS listed drug - hit the Australian market. Administered intravenously, Keytruda, is now used to treat an ever-growing list of cancers.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.